Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Soleno Therapeutics (SLNO) Profit After Tax (2016 - 2026)

Soleno Therapeutics has reported Profit After Tax over the past 9 years, most recently at $43.4 million for Q4 2025.

  • Quarterly Profit After Tax changed N/A to $43.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $20.9 million for FY2025, 111.88% up from the prior year.
  • Profit After Tax was $43.4 million for Q4 2025 at Soleno Therapeutics, up from $26.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $43.4 million in Q4 2025 and troughed at -$43.8 million in Q1 2025.